Free Trial

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Andrew Gengos Buys 5,000 Shares

Terns Pharmaceuticals logo with Medical background

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Andrew Gengos bought 5,000 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were purchased at an average cost of $3.95 per share, for a total transaction of $19,750.00. Following the acquisition, the chief financial officer now directly owns 15,000 shares in the company, valued at $59,250. This trade represents a 50.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Andrew Gengos also recently made the following trade(s):

  • On Friday, June 13th, Andrew Gengos purchased 10,000 shares of Terns Pharmaceuticals stock. The stock was purchased at an average cost of $3.73 per share, with a total value of $37,300.00.

Terns Pharmaceuticals Price Performance

Shares of NASDAQ:TERN traded up $0.10 during trading on Thursday, reaching $4.00. The company had a trading volume of 749,211 shares, compared to its average volume of 1,498,111. The company has a fifty day moving average of $3.12 and a two-hundred day moving average of $3.99. Terns Pharmaceuticals, Inc. has a 12 month low of $1.87 and a 12 month high of $11.40.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.03. On average, equities research analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TERN has been the topic of several research analyst reports. William Blair reaffirmed a "market perform" rating on shares of Terns Pharmaceuticals in a report on Friday, March 21st. BMO Capital Markets decreased their target price on Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 price target on shares of Terns Pharmaceuticals in a report on Monday, April 21st. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.63.

Check Out Our Latest Stock Report on TERN

Hedge Funds Weigh In On Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Thrive Wealth Management LLC bought a new position in shares of Terns Pharmaceuticals during the 1st quarter valued at about $29,000. Landscape Capital Management L.L.C. purchased a new stake in Terns Pharmaceuticals in the fourth quarter worth approximately $73,000. Townsquare Capital LLC bought a new position in Terns Pharmaceuticals during the fourth quarter valued at approximately $76,000. Vontobel Holding Ltd. bought a new position in Terns Pharmaceuticals during the first quarter valued at approximately $39,000. Finally, Oxford Asset Management LLP purchased a new position in shares of Terns Pharmaceuticals during the fourth quarter worth approximately $86,000. 98.26% of the stock is currently owned by hedge funds and other institutional investors.

Terns Pharmaceuticals Company Profile

(Get Free Report)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Recommended Stories

Insider Buying and Selling by Quarter for Terns Pharmaceuticals (NASDAQ:TERN)

Should You Invest $1,000 in Terns Pharmaceuticals Right Now?

Before you consider Terns Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.

While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines